Sign in

J90 on Frankfurt Stock Exchange

NurExone Biologic Inc.

Logo: nurexone.com4

NurExone Biologic Inc. is a Canadian biotechnology company developing exosome-based therapeutics.1 It is headquartered in Calgary, Canada.1 Its shares trade on Frankfurt Stock Exchange under the symbol J90.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerJ90 on Frankfurt Stock Exchange1
  • Industrybiotechnology1
  • HeadquartersCalgary, Canada1
  • Websitenurexone.com
  • Listed onFrankfurt Stock Exchange (J90), OTCQB Marketplace (NRXBF), TSX Venture Exchange (NRX.V)1
  • Legal formCorporation3
  • LEI25490047UWNZ2P8ESB773
  • StatusActive3
  • LEI statusIssued and current3
  • Registered address1 Adelaide Street East, M5C 2V9 Toronto, Canada3
  • Registered withMinistry of Government and Consumer Services, 10012115333

See how the biggest companies compare on our leaderboards

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerEran Ovadya named Oct 2, 2023 to Aug 21, 20265
  • Executive Officer, DirectorLior Shaltiel named Oct 2, 2023 to Aug 21, 20265
  • Executive Officer, DirectorYoram Drucker named Mar 25, 2024 to Aug 21, 20265
  • DirectorDavid Stolick named Aug 21, 20265
  • DirectorEyal Gabbai named Mar 18, 2026 to Aug 21, 20265
  • DirectorOded Orgil named Mar 25, 2024 to Aug 21, 20265
  • DirectorJames Richardson named Mar 25, 2024 to Jul 2, 20266
  • DirectorGadi Riesenfeld named Oct 2, 2023 to Aug 27, 20257
  • DirectorJames 40 Richardson named Oct 2, 2023 to Jan 9, 20248
  • DirectorOded 40 Orgil named Oct 2, 2023 to Jan 9, 20248
  • DirectorYoram 40 Drucker named Oct 2, 2023 to Jan 9, 20248

Timeline

  1. Jun 27, 2011Founded NurExone Biologic Inc. is founded3

Filings

11 filings to the SEC since October 2021: 11 private raises. The latest 11:

  1. Aug 21, 2026D EDGAR
  2. Jul 2, 2026D EDGAR
  3. Mar 18, 2026D EDGAR
  4. Aug 27, 2025D EDGAR
  5. Apr 22, 2025D EDGAR
  6. Jan 22, 2025D EDGAR
  7. Mar 25, 2024D EDGAR
  8. Mar 25, 2024D EDGAR
  9. Mar 25, 2024D EDGAR
  10. Jan 9, 2024D EDGAR
  11. Oct 2, 2023D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$6.7M 2023–2026
Money received by yearMoney received by year, 2023–2026: $6.7M in all. Private raises (Form D) $6.7M.$0$1M$2M$3M2023 · Private raises (Form D): $742.2K20232024 · Private raises (Form D): $2.6M20242025 · Private raises (Form D): $2.2M20252026 · Private raises (Form D): $1.2M2026
Figures by year
YearPrivate raises (Form D)Total
2026$1.2M$1.2M
2025$2.2M$2.2M
2024$2.6M$2.6M
2023$742.2K$742.2K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Aug 20, 2026Raised $450,456 in a private offering of equity5 Form D: 2 investors so far Form D
  2. Jun 30, 2026Raised $441,779 in a private offering of equity6 Form D: 2 investors so far Form D
  3. Mar 10, 2026Raised $279,910 in a private offering of equity9 Form D: 4 investors so far Form D
  4. Aug 20, 2025Raised $147,846 in a private offering of equity7 Form D: $243,231 offered in all Form D
  5. Apr 9, 2025Raised $1.6 million in a private offering of equity10 Form D: $3.8 million offered in all Form D
  6. Jan 21, 2025Raised $434,512 in a private offering of equity11 Form D: 6 investors so far Form D
  7. Mar 22, 2024Raised $42,634 in a private offering of equity12 Form D: 1 investor so far Form D
  8. Mar 21, 2024Raised $1 million in a private offering of securities13 Form D: 4 investors so far Form D
  9. Mar 20, 2024Raised $430,296 in a private offering of equity14 Form D: 5 investors so far Form D
  10. Jan 4, 2024Raised $1.1 million in a private offering of equity8 Form D: $2.5 million offered in all Form D
  11. Aug 25, 2023Raised $742,166 in a private offering of equity15 Form D: 6 investors so far Form D

SEC filer profile

How NurExone Biologic Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNurExone Biologic Inc.2
  • CIK0001995074
  • Incorporated inOntario, Canada2
  • Fiscal year endsDecember 312
  • Business addressMinus 1 Entry, Ground Floor Of Bldg B, Gutwirth Industrial Park, Technion City, Haifa, Israel2
  • Phone972 52-48030342
  • On EDGAR sinceOct 2, 20232
  • Filings11 in all: D (11)2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15